“pinpoints the origins of each of the viruss components”
a little bit of this & a little bit of that. did they find the “made in” sticker?
Pwned.
9 deaths thus far, in a nation whos healthcare is supposedly so screwed up that the leftists, always activly searching for a crisis to exploit, will lie to the public, to pass national health care so we can be more like Mexico.
How many people have died in Mexico?
I’m eating Tylenols like candy, my head spins at the thought that the msm spins that Obama is looking out for us when I know it was the former president ERASING the mistake of Clinton defunding the CDC emergency medicines.
I’m sick. Sick and tired of hearing how Obama is alwawys the day late and dollar short Hawk, what a charlatan, what a truly empty suit.
In my time Iv’e met plenty of merchant marines, and thank God, as our current POTUS was worried about the “global” legal ramifications about shooting pirates - for two days, That the “On scene Commander” did a good thing, and let his crack team do what only that kind of team can do.
So I still ask, what is it that Obama hopes to change?
We have medicine against the spread of the current viral threat, that clinton defunded. And (once again campaign lie) Obama hires Clinton Hacks.
GOD BLESS GWB, I ain’t yer buddy, but at least you were real and true.
Thanks once again.
In this work, we study the consequences of sequence variations of the "2009 H1N1" (swine or Mexican flu) influenza A virus strain neuraminidase for drug treatment and vaccination. We find that it is phylogenetically more closely related to European H1N1 swine flu and H5N1 avian flu rather than to the H1N1 counterparts in the Americas. Homology-based 3D structure modeling reveals that the novel mutations are preferentially located at the protein surface and do not interfere with the active site. The latter is the binding cavity for 3 currently used neuraminidase inhibitors: oseltamivir (Tamiflu(R)), zanamivir (Relenza(R)) and peramivir; thus, the drugs should remain effective for treatment. However, the antigenic regions of the neuramidase relevant for vaccine development, serological typing and passive antibody treatment can differ from those of previous strains and already vary among patients.
Reviewers: This article was reviewed by Sandor Pongor and Aravind Lakshminarayanan Iyer.
I have too many windows open to try to open the pdf link.